Secure shopping
Healthcare and pharma
The Pharma & Healthcare industry is of vital importance for human and economic development, providing a wide range of goods and services relevant to the promotion of health at all stages in the healthcare process – from prevention and treatment to rehabilitation and palliative care. It is one of the fastest-growing industries, supported by profound demographic changes, the rising incidence of non-communicable diseases, and surging per capita health spending in both developed and emerging markets. The industry is also one of the major innovators, with increasing expenditures on development of new molecules, biotechnology and adoption of new technologies that provide advanced healthcare and ensure the longevity of the population.
The Pharma & Healthcare industry comprises the manufacture of pharmaceuticals for human and veterinary use, medical equipment and related supplies. It also includes providers of ambulatory health services, medical and diagnostic laboratories, hospitals, and nursing and residential care facilities.
In 2012-2017 Chile’s total health expenditure rose at a CAGR of 11.6%, driven by a solid increase of government spending on healthcare. In 2017, Chile allocated 8.1% of its GDP on healthcare, a figure that is bound to grow in the short term. ...
View more details
Expenditure on healthcare in Romania reached RON 35.2bn in 2015, according to data provided by Eurostat. Total expenditure on healthcare was equal to 4.94% of GDP in that year. The Romanian healthcare sector was characterised by the lowest per capita ...
View more details
Total expenditure on healthcare in Hungary in 2015 reached HUF 2,460bn, up by 6.3% y/y. Government and compulsory health care financing schemes made up 67% of the expenditure, followed by private out-of-pocket spending (29%). Voluntary healthcare ...
View more details
In 2016 Poland’s healthcare expenditure grew by 4.5% y/y to PLN 119.27bn, representing 6.4% of the GDP. Public healthcare spending in Poland is one of the lowest compared to the EU average, which hovers around 6.5 % of GDP. The bulk of the ...
View more details
Russia’s healthcare and pharmaceutical sector was badly affected by the 2015-2016 recession, which resulted in a sharp drop in government spending, while the weak rouble and high inflation cut into households’ disposable incomes. Though ...
View more details
In Q3 2017 China continued to implement healthcare reforms which resulted in further development and growth of the sector. According to a health management summit held in Beijing in late 2017, the country’s healthcare market will reach RMB 4 ...
View more details
China's healthcare system is hospital-centric, with public hospitals delivering approximately 90% of the inpatient and outpatient care consumed in the country in both hospitals and basic medical institutions. Nearly 40% of hospitals’ revenue is ...
View more details
The pharmaceutical sector in the Czech Republic generated a gross value added (GVA) of CZK 18.9bn in 2016, up by 8.2% y/y in real terms. It accounted for 0.44% of the total GVA in the economy in 2016. The sector employed 9,438 workers. Total ...
View more details
Brazil is the eighth-largest pharmaceutical market in the world. In 2016, the retail drug market, based on ex-factory prices, rose by 15.5% y/y to BRL 87.2bn, supported by upward price dynamics and steady demand for innovative patented drugs. In ...
View more details
China's healthcare system is hospital-centric, with public hospitals delivering approximately 90% of the inpatient and outpatient care consumed in the country in both hospitals and basic medical institutions. Nearly 40% of hospitals’ revenue is ...
View more details